GVK Biosciences Joins ResearchPoint Global

Addition of India-based CRO expands reach of worldwide clinical organization

15-Jan-2010 - India

Maximum binding capacity in ion exchange chromatography

Advanced CHO Cell Line Development Technology for In-House Implementation

Gas chromatography detector for fluorine and sulfur compounds

ResearchPoint Global (RPG) announced its newest member, GVK Biosciences (GVK BIO). GVK BIO provides RPG with access to an extensive network of experienced and proven investigative sites and country-specific regulatory, clinical and technical expertise.

As the growth of India’s participation in global clinical programs continues to increase at a rapid pace, RPG strategically sought to expand its reach to this region. According to The Goldman Sachs Group, Inc., “India presents an attractive region for clinical trials given a population of over one billion, a large number of English-speaking patients, and a well developed information technology industry.” 1

RPG’s expansion into India offers numerous advantages for running clinical trials: a large population, qualified medical personnel, and well-established regulations. GVK BIO complements RPG’s current presence in the Americas, Europe (Western, Central, and Eastern) and Africa.

“RPG is strategically expanding our global footprint with qualified, like-minded CROs who have extensive drug development experience across a broad range of therapeutic areas,” said Matt Walker, Executive Vice President of Marketing and Business Development with ResearchPoint, a member of RPG. “GVK Biosciences has built an exceptional reputation as a full-service clinical service provider in India and we look forward to leveraging their deep local knowledge for the benefit of our clients.”

https://www.bionity.com/en/news/111779/gvk-biosciences-joins-researchpoint-global.html